Announced details
Treatment for patients with unresectable, recurrent or advanced pancreatic cancer receiving third-line or later treatment
As of the latest point in time, the survival rate for all subjects under double-blind conditions was 71.8%, and median OS was approximately 7.2 months
78 patients enrolled in the Phase 2 portion (enrollment completed)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Only a general statement is provided that a median OS of approximately 3–4 months for patients with advanced pancreatic cancer receiving third-line or later treatment has been reported; study and institution names: Not disclosed
| Item | Details |
|---|---|
| Names of Products / Services Covered | DFP-17729 (tumor microenvironment modulator) |
| Applicable area | Treatment for patients with unresectable, recurrent or advanced pancreatic cancer receiving third-line or later treatment |
| Quantitative Effects | As of the latest point in time, the survival rate for all subjects under double-blind conditions was 71.8%, and median OS was approximately 7.2 months |
| Usage history | 78 patients enrolled in the Phase 2 portion (enrollment completed) |
| Source | Only a general statement is provided that a median OS of approximately 3–4 months for patients with advanced pancreatic cancer receiving third-line or later treatment has been reported; study and institution names: Not disclosed |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The final efficacy assessment for the Phase 2 portion has not yet been completed, and the data remain double-blinded at this time. Follow-up and analysis will therefore continue to determine whether to continue the trial and whether to proceed to Phase 3.